Tesamorelin: what Egrifta WR is approved to treat

The July 2026 Egrifta WR label identifies tesamorelin for reduction of excess abdominal fat in adults with HIV and lipodystrophy. It explicitly says the product is not indicated for weight-loss management and has a weight-neutral effect. This is a useful example of why an appealing peptide mechanism cannot be turned into a general weight-loss promise. DailyMed: Egrifta WR current label

The label says long-term cardiovascular safety has not been established and asks clinicians to consider continuation if visceral fat does not decrease. It also says Egrifta WR and Egrifta SV differ in preparation and storage and are not substitutable. It does not establish that a research-use tesamorelin powder is equivalent to Egrifta WR. FDA’s Purple Book identifies the approved tesamorelin product record, while the label supplies the clinical boundaries. DailyMed: Egrifta WR current label FDA Purple Book: Egrifta WR

A patient with HIV-related lipodystrophy needs care that accounts for HIV treatment, metabolic health, other medicines, and the goal of reducing excess abdominal fat. The clinician should use the exact label and coordinate with the patient’s existing team. FDA’s labeling FAQ explains the role of indications, warnings, and patient materials. This article cannot diagnose lipodystrophy or recommend a treatment regimen. FDA: Labeling FAQ for prescription medicines

Compounded medicines are not FDA-approved, and approval of Egrifta WR cannot be borrowed for a different finished product. Ask a clinician why any proposed preparation is medically appropriate and what evidence directly supports it. Confirm specialist access, insurance coverage, and the dispensing arrangement directly with the care team. FDA: Compounding and the FDA Q&A

The label’s abdominal-fat indication is tied to HIV-associated lipodystrophy, not an ordinary waist-size concern. Even if a study showed a change in visceral fat, that does not automatically establish reduced heart events, longer life, or general weight loss. The label itself identifies limitations about long-term cardiovascular safety and weight-neutral effects. Read those limits alongside the headline benefit. DailyMed: Egrifta WR current label

Ask the treating HIV clinician which diagnosis is documented, what other causes of abdominal change were considered, and how response would be assessed. Confirm whether the exact approved product is proposed and how it fits existing antiretroviral and metabolic care. A research-only tesamorelin listing should not be treated as a route into the same evidence package. The decision requires specialty clinical context and product traceability. FDA Purple Book: Egrifta WR

A reduction in measured abdominal fat is not the same outcome as improved cardiovascular survival, HIV control, or overall weight loss. Ask which outcome the studies actually measured and what the label says remains unknown. FDA’s label specifically addresses these limits. That is why a broad “fat-loss peptide” headline misrepresents a much narrower approved use. DailyMed: Egrifta WR current label